BioSpectator Inc – Weekly Recap

BioSpectator Inc this week spotlighted a series of Korean oncology innovators advancing differentiated antibody and ADC platforms toward the clinic. Coverage focused on emerging IND timelines, bispecific and trispecific engineering strategies, and how these programs aim to improve efficacy and safety in solid tumors.

Y-Biologics was highlighted for its cis-acting trispecific IL-2 antibody strategy that targets PD-1–expressing T cells in the tumor microenvironment. The company plans IND submissions next year for two candidates benchmarked against ivonescimab and Bristol Myers Squibb’s Opdualag.

Its platform is testing two IL-2 variants, including an attenuated alpha-biased form and a non-alpha version that removes IL-2Rα binding. The goal is localized IL-2 activation on PD-1+ T cells to enhance antitumor activity while limiting peripheral cytokine toxicity.

ABL Bio featured prominently with ABL206, a B7-H3xROR1 bispecific ADC that recently secured U.S. FDA clearance for a Phase 1 trial, with first patient dosing expected around late May. The design targets co-expression of B7-H3 and ROR1 to increase tumor selectivity and potentially mitigate off-tumor effects.

Preclinical data cited in BioSpectator’s coverage show reduced tumor growth in models relapsing after I-DXd and a high non-severely toxic dose of 60 mg/kg in primates. These findings support ABL206 as a next-generation B7-H3 ADC candidate in a competitive global market.

ABL Bio’s EGFR x MUC1 ADC ABL209 (NEOK002) was also profiled as it approaches Phase 1 initiation in the second quarter. The asset employs a 1+1 bispecific format with the TOP1 inhibitor payload tevatecan, already used in CLDN18.2 ADC IBI343.

ABL209 is engineered with roughly 60-fold lower EGFR affinity versus marketed antibodies and targets a distinct MUC1 domain to address prior efficacy loss from MUC1 shedding. Nonclinical data published in Molecular Cancer Therapeutics were presented at AACR 2026, underscoring scientific validation.

BioSpectator additionally covered ReCerise Therapeutics’ first-in-class TM4SF5 antibody RCT1213, which could enter clinical testing as early as next year. TM4SF5 is linked to gastrointestinal cancers, including hepatocellular carcinoma, colorectal cancer, and pancreatic ductal adenocarcinoma.

RCT1213 aims to reprogram an immune-resistant tumor microenvironment into an immune-permissive state, with mechanisms and preclinical data shared in an AACR oral session. Overall, BioSpectator’s reporting points to growing innovation across Korean immuno-oncology and ADC pipelines, with multiple assets transitioning toward early clinical validation.